14 completed. 14 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow Rett Syndrome: new trials by email Literature Review of Rett Syndrome trials Research Report on Rett Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome Drug: Bionetide, Placebo - Rett Syndrome | Phase 2 / Phase 3 | Completed | Biomed Industries, Inc. | 187 | 2024-03-15 | 2025-02-27 |
| Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT) NTI164 - Rett Syndrome | Phase 1 / Phase 2 | Completed | Fenix Innovation Group | 14 | 2023-09-20 | 2026-09-09 |
| ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 oral liquid, Placebo oral liquid - Rett Syndrome | Phase 2 / Phase 3 | Completed | Anavex Life Sciences Corp. | 92 | 2020-07-01 | 2023-08-21 |
| A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Ketamine - Rett Syndrome | Phase 2 | Completed | Rett Syndrome Research Trust | 23 | 2019-03-12 | 2024-05-28 |
| Study of ANAVEX2-73 in Patients With Rett Syndrome ANAVEX2-73, Placebo - Rett Syndrome | Phase 2 | Completed | Anavex Life Sciences Corp. | 31 | 2019-02-28 | 2021-01-12 |
| A Safety Study of NNZ-2566 in Pediatric Rett Syndrome NNZ-2566, Placebo - Rett Syndrome | Phase 2 | Completed | Neuren Pharmaceuticals Limited | 82 | 2016-03-01 | 2020-08-14 |
| Pharmacological Treatment of Rett Syndrome With Statins Lovastatin - Rett Syndrome | Phase 2 | Completed | Montefiore Medical Center | 20 | 2015-07-01 | 2019-07-12 |
| Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Glatiramer Acetate - Rett Syndrome | Phase 2 | Completed | Montefiore Medical Center | 10 | 2013-08-01 | 2018-11-05 |
| Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome fingolimod (FTY720) - Rett's Syndrome | Phase 1 / Phase 2 | Completed | University Hospital, Basel, Switzerland | 6 | 2013-08-01 | 2018-06-15 |
| A Safety Study of NNZ-2566 in Patients With Rett Syndrome NNZ-2566, Placebo - Rett Syndrome | Phase 2 | Completed | Neuren Pharmaceuticals Limited | 67 | 2013-03-01 | 2018-02-05 |
| Treatment of Rett Syndrome With Recombinant Human IGF-1 Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo - Rett Syndrome | Phase 2 | Completed | Boston Children's Hospital | 30 | 2013-01-01 | 2018-03-26 |
| Phase 2 Study of EPI-743 for Treatment of Rett Syndrome EPI-743, Placebo - Rett Syndrome | Phase 2 | Completed | Edison Pharmaceuticals Inc | 24 | 2013-01-01 | 2018-07-26 |
| Placebo Controlled Trial of Dextromethorphan in Rett Syndrome dextromethorphan, placebo - Rett Syndrome | Phase 2 | Completed | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 57 | 2012-03-01 | 2018-12-04 |
| Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Administration of a high dose of desipramine, Administration of a low dose of desipramine, Administration of a placebo - Rett Syndrome | Phase 2 | Completed | Assistance Publique Hopitaux De Marseille | 36 | 2009-02-17 | 2018-07-26 |
Ataxia (2) · Autistic Disorder (2) · Autism Spectrum Disorder (1) · Genetic Diseases, X-Linked (1) · X-Linked Intellectual Disability (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Genetic Diseases, Inborn (14) · Heredodegenerative Disorders, Nervous System (14) · Intellectual Disability (14) · Nervous System Diseases (14) · Neurobehavioral Manifestations (14) · Neurologic Manifestations (14) · Genetic Diseases, X-Linked (13) · X-Linked Intellectual Disability (13) · Child Development Disorders, Pervasive (3) · Mental Disorders (3) · Neurodevelopmental Disorders (3) · Autism Spectrum Disorder (2) · Dyskinesias (2) · Pathological Conditions, Signs and Symptoms (2)
Injections (2) · tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (2) · trofinetide (2) · DNA, Ribosomal (1) · Desipramine (1) · Dextromethorphan (1) · Fingolimod Hydrochloride (1) · Glatiramer Acetate (1) · Ketamine (1) · Lovastatin (1) · Sodium Chloride (1) · Water (1) · alpha-tocotrienol quinone (1) · mecasermin (1)
Anavex Life Sciences Corp. (2) · Montefiore Medical Center (2) · Neuren Pharmaceuticals Limited (2) · Assistance Publique Hopitaux De Marseille (1) · Biomed Industries, Inc. (1) · Boston Children's Hospital (1) · Edison Pharmaceuticals Inc (1) · Fenix Innovation Group (1) · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1) · Rett Syndrome Research Trust (1) · University Hospital, Basel, Switzerland (1)
United States (9) · Australia (3) · Canada (1) · France (1) · Italy (1) · Switzerland (1) · United Kingdom (1)
Alan Percy, MD (2) · Timothy Feyma, MD (2) · Aleksandra Djukic, MD PhD (1) · Arthur Beisang, MD (1) · Daniel G Glaze, M.D. (1) · Daniel Glaze, MD (1) · David Nguyen, PhD (1) · Eric Marsh, MD (1) · Jana von Hehn, PhD (1) · Jeff Neul, MD (1) · Jeffrey L Neul, M.D., Ph.D. (1) · Jeffrey Neul, MD, PhD (1) · Josette Mancini (1) · Lloyd L. Tran, PhD (1) · Ludwig Kappos, Prof. (1)
PMID 37460385, PMID 38363467, PMID 27363291, PMID 29468173, PMID 33395098, PMID 33407685, PMID 39856538